Drug intelligence / Profile preview

LPT-201

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules

Overview

LPT-201 is a 'super generic' drug candidate being developed by LitePharmTech. It is an improved formulation of an existing pharmaceutical product intended for nutrition supply. As a super generic, it likely utilizes a 505(b)(2)-like regulatory pathway, aiming to offer advantages such as improved bioavailability, reduced side effects, or enhanced patient compliance compared to the original reference drug. The project is currently in the preclinical stage of development, with research focused on optimizing the delivery and therapeutic profile of the nutritional agent.

Beyond the preview

Go deeper on LPT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-201.

Explore the full profile